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Abstract 
Osteoarthritis (OA) is a degenerative joint disease characterised in part by destruction of 
articular cartilage. There are currently no disease-modifying drugs to treat OA, with joint 
replacement the only treatment offered to patients at end-stage disease. With age the major 
risk factor for OA, the number of patients is predicted to double by 2030. An understanding 
of the role of bioactive molecules from the habitual diet on joint health offers a novel way in 
which to prevent the onset or slow the progression of OA. Our research has indicated that 
sulforaphane (SFN), gained from the consumption of cruciferous vegetables, particularly 
broccoli, could impact upon articular cartilage in laboratory models of OA because (1) it 
decreased the cytokine-induced expression of cartilage-degrading proteinases from 
chondrocytes (cartilage cells); (2) it prevented the cytokine-induced degradation of cartilage 
explants; and (3) it attenuated cartilage destruction in a murine model of OA. The major 
mechanism of action for SFN in human articular chondrocytes was inhibition of NFB, not 
activation of Nrf2 nor inhibition of histone deacetylases. A proof-of-principle human trial was 
performed to measure uptake of SFN, or its metabolites, in the human knee joint following a 
broccoli-rich diet, and the expression or levels of several genes and proteins in cartilage, fat 
and synovial fluid were also measured. Data from this trial are about to be published. 
Overall, these findings support the utility of SFN in the prevention or treatment of OA. The 
proof of this requires an appropriately designed clinical trial of pain and function which we 
are currently pursuing.   
 
  
Osteoarthritis (OA) is a degenerative joint disease characterised by degradation of articular 
cartilage as well as thickening of the subchondral bone and the formation of osteophytes at 
the joint margin (Goldring & Goldring 2006). It is a leading cause of disability in the UK. 
Approximately 8.5 million people in the UK suffer from moderate to severe OA (Arthritis Care 
2012). There is a lack of effective, disease-modifying drugs available to treat OA and the 
drugs that target symptomatic pain are often inadequate (McHughes & Lipman 2006). Joint 
replacement is the only treatment offered to patients reaching end-stage OA disease with 66 
436 hip and 77 578 knee replacements performed in 2011 (Porter et al. 2012). 
Two major risk factors for OA are age (most patients are >45 years of age and the greatest 
morbidity is seen in patients >60 years of age) (Shane Anderson & Loeser 2010) and obesity 
(Richmond et al. 2013). With an ageing population and increasing rates of obesity, OA is a 
growing public health and economic burden. Though studies show high variability, direct 
health costs of OA have been estimated at approximately £1 billion per year, with indirect 
costs at approximately £3.5 billion in the UK (Chen et al. 2012).  Given the current 
demographic trend toward an older population, OA, for which age is an important risk factor, 
will be an increasing burden on society with 17 million OA patients predicted for 2030. The 
ability to slow or stop progression of the disease would significantly improve both quality of 
life and the economic burden of OA. 
There are many issues which make drug development in OA problematic, including a lack of 
biomarkers and the need for a low toxicity profile in this non-life threatening disease. An 
alternative strategy is to focus on compounds in the UK population’s diet which may reduce 
the risk of developing or slow the progression of osteoarthritis. Dietary modification or 
increased intake of specific dietary constituents is attractive both in terms of risk/benefit ratio 
and implementation (Green et al. 2013). 
 
The function of cartilage and its maintenance 
Articular cartilage which lines the ends of long bones, functions to allow low friction 
movement of the joint, and to distribute force correctly to the underlying bone when 
movement occurs. Resident cells, the chondrocytes, are sparsely distributed throughout 
cartilage and must maintain and turnover the cartilage extracellular matrix (ECM) which is 
crucial to tissue function (Goldring 2006). Cartilage ECM is mainly made up of type II 
collagen and the proteoglycan, aggrecan. These components can be degraded by 
proteolytic enzymes. Type II collagen is principally turned over by enzymes from the matrix 
metalloproteinase family [MMPs, e.g. MMP-13 (Cawston & Wilson 2006)], whilst enzymes 
from the ‘a disintegrin and metalloproteinase domain with thromospondin motifs’ [ADAMTS, 
e.g. ADAMTS-5 (Fosang et al. 2008)] family metabolise the latter. An imbalance between the 
activity of these enzymes and their inhibitors (the tissue inhibitors of metalloproteinases) is 
thought to underlie cartilage destruction in OA (Burrage & Brinckerhoff 2007).   
 
Sulforaphane and osteoarthritis 
Sulforaphane (1-isothiocyanato-4-methylsulphinylbutane; SFN) is an isothiocyanate (ITC) 
obtained in the diet through consumption of cruciferous vegetables, particularly broccoli 
(Juge et al. 2007). SFN (and other ITCs) are synthesised in plant cells as glucosinolates 
(glucoraphanin in the case of SFN).  Upon disruption (e.g. by chewing or chopping) 
glucosinolates are converted to ITCs by an enzyme myrosinase (which is normally physically 
separated from the glucosinolate). Myrosinase is also present in enteric microflora and a 
significant proportion of ingested glucoraphanin (up to 20%) in humans can be converted to 
SFN in the intestine (Conaway et al. 2000). In humans, 2 hours after consumption of 100 g 
of broccoli, prepared as a soup, an average peak plasma concentration of 2.2 µM SFN was 
measured, with 7.3 µM achieved with a high-glucosinolate broccoli (Gasper et al. 2005). 
SFN is a potent inducer of phase II (detoxification) metabolism via activation of the Nrf2 
transcription factor, which binds to an antioxidant response element (ARE) in cognate genes  
including a variety of ‘indirect’ antioxidants (Dinkova-Kostova & Talalay 2008; Juge et al. 
2007). Thus the action of SFN is protective from oxidative stress (Dinkova-Kostova & Talalay 
2008). SFN has also been shown to modulate other signalling pathways including the MAP 
kinase (ERK, p38 and JNK), Akt-PI3K and NFB pathways (Heiss et al. 2001; Jakubikova et 
al. 2005) in a cell-type dependent manner. There is also a literature suggesting that SFN and 
related compounds are inhibitors of HDACs both in vitro and in vivo (Dashwood & Ho 2007). 
In chondrocytes, high shear stress is pro-apoptotic and promotes ECM degradation. Shear 
stress (via JNK2 and c-Jun) induces cyclooxygenase-2 expression and activity and 
suppresses PI3K activity leading to repression of Nrf2-mediated transcription. This reduces 
the antioxidant capacity of chondrocytes under shear stress and contributes to their 
apoptosis. Addition of SFN, which induces Nrf2-mediated transcription, negates shear-
mediated apoptosis (Healy et al. 2005). SFN has been shown to abrogate the IL-1 mediated 
induction of MMP-1, -3 and -13 in human articular chondroyctes. SFN was able to inhibit the 
activation of JNK and NFκB in these cells (Kim et al. 2009). In a mouse model of rheumatoid 
arthritis, SFN induced apoptosis in the proliferating synovium, albeit at high dose (peak 
plasma concentration of 200 µM following intraperitoneal administration) and showed 
efficacy in this model of inflammatory arthritis (Kong et al.2010). Dosing at this level every 
other day for 5 weeks showed no overt toxicity in this model. 
These data encouraged the collaboration of our team at the University of East Anglia to 
investigate the role of SFN in OA under funding from the Biotechnology and Biological 
Sciences Research Council (BBSRC) Diet and Health Research Industry Club (DRINC), with 
data from animal models supported by Arthritis Research UK. 
 
Results of the research 
The effect of SFN was investigated in three laboratory models of OA involving cells, tissue 
explants and animals. This was followed by a proof-of-principle human study (Davidson et al. 
2013).   
The first model investigated was the expression and production of cartilage-degrading 
metalloproteinases by cartilage cells (chondrocytes). Primary human articular chondrocytes 
(HACs) were isolated from cartilage taken at joint replacement surgery and used at early 
passage in monolayer culture to maintain phenotype. The expression of cartilage-degrading 
metalloproteinases, MMP1 and MMP13 (collagen-degrading enzymes), ADAMTS4 and 
ADAMTS5 (aggrecan-degrading enzymes) acted as a surrogate marker of cartilage 
destruction. The expression of these genes was induced using a combination of IL-1 and 
oncostatin M and this was dose-dependently reduced by the addition of SFN across a 2.5 – 
10 µM dose-range (measured by qRT-PCR). The levels of protein for MMP-1 and MMP-13 
followed the same pattern. SFN could also inhibit IL-1-induced MMP1 and MMP13 
expression in primary human synovial fibroblasts too (with no measurable expression of the 
ADAMTS genes). We investigated the role of the transcription factor Nrf2 in the repression of 
the metalloproteinase genes as a possible mechanism-of-action for SFN. Sulforaphane was 
able to induce expression of the haemoxygenase-1 gene in HACs, known to be dependent 
on Nrf2 and this was confirmed by siRNA knockdown. However, the repression of IL-1/OSM-
induced MMP1 and MMP13 expression was not Nrf2 dependent. Interestingly in HACs, we 
could find no evidence of SFN acting as a histone deacetylase inhibitor. We measured the 
impact of SFN with or without IL-1 on the activation of mitogen-activated protein kinase 
signalling: ERK, JNK and p38 MAP kinases. The IL-1-induced phosphorylation of JNK and 
p38 MAPK was sustained for a longer time in the presence of SFN.   
The clearest mechanism by which SFN acted in HACs was via the inflammatory NFB 
pathway. Sulforaphane was able to delay the reaccumulation of IB following NFB 
activation by IL-1, indicating inhibition of the pathway. This was reinforced by the inhibition 
by SFN of the IL-1 induction of an NFB-responsive luciferase reporter. The IL-1-induced 
expression of a number of known NFB-responsive genes was also dose-dependently 
inhibited by SFN. However, neither phosphorylation of p65, nor the translocation of p65 to 
the nucleus were inhibited by SFN. Using electrophoretic mobility shift assays, we 
demonstrated that SFN added to cells at 10 µM could directly block the binding of a p50/p65 
complex to its cognate response element, but if this SFN was added exogenously to the 
binding reaction, it was only effective at high concentrations (>100 µM). When 10µM SFN 
was added to HACs, this led to the rapid intracellular accumulation of SFN-GSH to a peak 
concentration of >200 µM by 10-15 minutes. At this concentration, exogenous SFN-GSH 
was able to block p50/p65 DNA binding and this was redox sensitive (to dithiothreitol), 
suggesting a direct mode of NFB inhibition as previously described (Heiss et al. 2001). 
In a second model, we measured the ability of SFN to block the release of extracellular 
matrix components from explants of cartilage. This utilised bovine nasal cartilage as a robust 
source of tissue from young animals which degrades reproducibly in culture in response to 
IL-1/OSM stimulation. In this tissue, breakdown of proteoglycan occurs over 2 days and that 
of collagen over 14 days. The addition of SFN into the culture, led to a dose-dependent 
inhibition in the release of glycosaminoglycan (as a measure of proteoglycan breakdown) at 
day 2, and hydroxyproline (as a measure of collagen breakdown) at day 14. The effective 
dose range was higher than in isolated cells, over 5-20 µM. 
Funded by Arthritis Research UK, we also explored efficacy of SFN in a third model, the 
‘destabilisation of the medial meniscus’ (DMM) murine model of OA. Mice were fed on a 
SFN-rich chow which delivered approximately 3 µmoles SFN/day and underwent resection 
of the medial meniscotibial ligament. This leads to osteoarthritic lesions in the cartilage at 1-
3 months post-surgery. In mice fed the SFN-rich chow, there was a significant reduction in 
cartilage destruction at 12 weeks compared to the control diet. Microarray analysis of the 
mouse knee joints showed that a number of genes increased expression at day 7 after 
surgery in the control chow-fed mice, but not in the SFN chow-fed mice. Amongst these 
were Col2a1 and Col10a1, both known to be involved in cartilage extracellular matrix and, in 
part, inducible by NFB. 
Within the DRINC-funded study, in order to begin to translate our findings from the 
laboratory and animal models to human we undertook a proof-of-principle trial in humans.  
This randomised, parallel-design trial involving 40 patients with knee OA undergoing total 
knee replacement. After a week-long washout period, where all patients consumed a low 
glucosinolate diet, participants were randomised to either a low (all known glucosinolates 
excluded from the diet) or high glucosinolate diet (consisting of 100 g per day of a high 
glucosinolate broccoli, 1.8 µmols g-1) for 14 days ahead of surgery. Blood samples were 
taken immediately after the washout period, then after the 14 day dietary intervention prior to 
surgery. At surgery, synovial fluid, cartilage and adipose tissue were collected. The primary 
endpoints of this study were the detection of isothiocyanates in plasma and synovial fluid, 
with secondary endpoints of synovial fluid proteome analysis, cartilage degradation rate in 
vitro and plasma biomarker analysis. This research has been completed and is currently 
being written up for publication.  
These data support the utility of SFN in the prevention or treatment of OA. The proof of this 
requires an appropriately designed clinical trial of pain and function which we are currently 
pursuing. If efficacy is proven, then health professionals will have an evidence base on 
which to advise patients about dietary intervention for OA. Moreover, our research 
methodology provides a paradigm for understanding the role of other dietary factors in OA.  
If our research does show that an increased intake of SFN impacts upon pain and function, 
and potentially the structural progression of OA, this also highlights the need for a deeper 
knowledge of mechanism-of-action which would inform therapeutic strategies in OA. 
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